CMR-based assessment of long-term effects of tafamidis in patients with cardiac transthyretin amyloidosis
Substantial worsening of clinical symptoms, serum biomarkers, and imaging parameters occurred in both tafamidis-treated and tafamidis-naïve ATTR-CM patients within a follow-up period of approximately 2 years. However, the "extent of worsening" is significantly lower in the tafamidis-treated compared to the tafamidis-naïve patients.
Authors
- Claudia Meier (ORCID: https://orcid.org/0000-0003-3097-3500)
- Khuraman Isgandarova (ORCID: https://orcid.org/0000-0002-3566-4822)
- Volker Vehof
- Philipp Stalling
- Michael Bietenbeck (ORCID: https://orcid.org/0000-0002-1040-5760)
- Alexandru Zlibut (ORCID: https://orcid.org/0000-0002-1478-8156)
- Maria Theofanidou
- Ali Yılmaz (ORCID: https://orcid.org/0000-0003-4526-8679)
- Nuriye Akyol
- Redouane Bouras
Institutions
- University Hospital Münster (DE)
Publication Details
- Journal
- Clinical Research in Cardiology
- Published
- 2025-10-27
- DOI
- https://doi.org/10.1007/s00392-025-02691-8
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00